ISRCTN72126158 https://doi.org/10.1186/ISRCTN72126158

A Double Blind, Randomised, Placebo Controlled Study of Farlutal in the Treatment of Weight Loss in Patients Undergoing Radiotherapy for Head and Neck Cancer

Submission date 19/08/2002	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol
Registration date 19/08/2002	**Overall study status** Completed	[_] Statistical analysis plan [_] Results
Last Edited 03/03/2008	**Condition category** Cancer	[_] Individual participant data [_] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

MPA8801

Study information

Scientific Title

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Not Specified

Participant information sheet

Health condition(s) or problem(s) studied
Head and Neck Cancer

Interventions
1. Group A: Oral medroxyprogesterone acetate 500 mg twice daily for a maximum of 12 weeks
2. Group B: Placebo tablets twice daily for a maximum of 12 weeks

Intervention Type
Other

Phase
Not Specified

Primary outcome measure
Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date
19/08/2000

Completion date
19/08/2005

Eligibility

Key inclusion criteria
1. Aged >18 years
2. Squamous cell carcinoma of the head and neck
3. Not known to have or suspected of having early breast cancer
4. No known hypersensitivity to medroxyprogesterone acetate
5. No medical contraindications to treatment

Participant type(s)
Patient

Age group
Not Specified

Lower age limit
18 Years

Sex
Not Specified

Target number of participants
Not provided at time of registration

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
19/08/2000

Date of final enrolment
19/08/2005

Locations

Countries of recruitment
England

Italy

United Kingdom

Study participating centre
UKCCCR Register Co-ordinator
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Farmitalia Carlo Erba (Italy)

Sponsor details
-
-
Italy
-

Sponsor type
Industry

ROR
https://ror.org/03htt2d69

Funder(s)

Funder type
Not defined

Funder Name
Not provided at time of registration.

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration